Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
0(0%)
Results Posted
12%(2 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_1
3
16%
Ph not_applicable
6
32%
Ph phase_2
5
26%
Ph phase_3
2
11%
Ph phase_4
3
16%

Phase Distribution

3

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
3(15.8%)
Phase 2Efficacy & side effects
5(26.3%)
Phase 3Large-scale testing
2(10.5%)
Phase 4Post-market surveillance
3(15.8%)
N/ANon-phased studies
6(31.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(17)
Terminated(2)

Detailed Status

Completed17
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (15.8%)
Phase 25 (26.3%)
Phase 32 (10.5%)
Phase 43 (15.8%)
N/A6 (31.6%)

Trials by Status

completed1789%
terminated211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT01430351Phase 1

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

Terminated
NCT02084602Phase 4

Assessment of Artesunate/Mefloquine in the Peruvian Amazon

Completed
NCT00761020Not Applicable

Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection

Completed
NCT04347031Phase 2

A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

Completed
NCT02524444Phase 1

A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients

Completed
NCT02488980Phase 2

An Evaluation of Weekly Tafenoquine

Completed
NCT01976780Phase 4

In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy

Completed
NCT00499876Not Applicable

The Effect of Malaria on Disease Progression of HIV/AIDS

Completed
NCT00158574Phase 2

Kilimanjaro IPTi Drug Options Trial

Completed
NCT02324738Phase 4

Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects

Completed
NCT00746941Phase 1

Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)

Terminated
NCT00811421Not Applicable

Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy

Completed
NCT01132248Phase 2

Activity of Mefloquine Against Urinary Schistosomiasis

Completed
NCT00970879Phase 3

Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine

Completed
NCT01659281Not Applicable

Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand

Completed
NCT00373048Not Applicable

Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial

Completed
NCT00082576Phase 2

Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa

Completed
NCT00367653Phase 3

Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.

Completed
NCT00127998Not Applicable

Antimalarial Drug Resistance in Mali

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19